Arnhold LLC Has $16.41 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Arnhold LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 1.8% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 570,019 shares of the biopharmaceutical company’s stock after buying an additional 10,161 shares during the quarter. Pfizer comprises 1.8% of Arnhold LLC’s holdings, making the stock its 17th biggest position. Arnhold LLC’s holdings in Pfizer were worth $16,411,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of PFE. Briaud Financial Planning Inc acquired a new position in Pfizer in the third quarter valued at about $30,000. GoalVest Advisory LLC raised its stake in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. acquired a new position in Pfizer in the third quarter valued at about $34,000. VisionPoint Advisory Group LLC grew its position in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new position in Pfizer in the fourth quarter valued at about $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 0.1 %

PFE stock traded down $0.03 during trading on Tuesday, hitting $25.61. The company had a trading volume of 37,889,007 shares, compared to its average volume of 41,962,758. The business has a 50-day moving average of $26.88 and a 200-day moving average of $28.26. Pfizer Inc. has a one year low of $25.20 and a one year high of $40.37. The stock has a market cap of $145.02 billion, a PE ratio of 71.14, a PEG ratio of 1.14 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same period in the previous year, the firm earned $1.14 earnings per share. The company’s revenue was down 41.3% compared to the same quarter last year. Research analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.56%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Guggenheim assumed coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.